Neoplasms – Bladder Cancer Research
The research program at Provita Profamilia concentrates on non‑muscle invasive bladder cancer, advancing immunotherapy strategies within the neoplasm therapeutic area.
- Combination immunotherapy with durvalumab and BCG
- Evaluation of disease‑free survival outcomes
- Safety profiling of intravesical treatments
- Comparative analysis against standard BCG therapy
Six investigators at the Piotrkow Trybunalski site are conducting two clinical trials that test a checkpoint‑inhibitor plus BCG regimen, aiming to improve long‑term disease control for patients with early‑stage bladder cancer.
